Idylla™ POLE-POLD1 mutation assay for molecular characterization and risk stratification of endometrial cancers: a retrospective multicenter validation study
Peter Frandsen(Copenhagen Zoo), Jesper Bonde(Hvidovre Hospital), Benjamin Goeppert(University of Bern), Khédoudja Nafa(Memorial Sloan Kettering Cancer Center), Karl Kashofer(Medical University of Graz), Oliver Scheiber(Graz University Hospital), Helle Pedersen(Hvidovre Hospital), Amir Momeni Boroujeni(Memorial Sloan Kettering Cancer Center), Ana Velasco(Hospital Universitari Arnau de Vilanova), Estrid Høgdall(Herlev Hospital), Alan Brown(Methodist Hospital), Jannie Bay(Hvidovre Hospital), Maria Arcila(Memorial Sloan Kettering Cancer Center), Sigurd F. Lax(Johannes Kepler University of Linz), Mohammed Atef Shrit(Miami Valley Hospital), Salima Mrabet-Dahbi(Klinikum Kassel), Christopher Knoeckel(University of Colorado Anschutz Medical Campus), Xavier Matias-Guiu(Hospital Universitari Arnau de Vilanova), Irina Bonzheim(University Children's Hospital Tübingen)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
August 11, 2026
Cited by 1
Related Papers
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication
|Brain Behavior and Immunity|2016|741
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
|Clinical Cancer Research|2011|574
Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells
|Transfusion|2007|507
Inferring expressed genes by whole-genome sequencing of plasma DNA
|Nature Genetics|2016|463
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
|Cancer and Metastasis Reviews|2020|334